Breaking News

Bioserv, Advantar Create Value Chain Alliance

March 18, 2013

To provide integrated service offerings

Bioserv Corp., a provider of cGMP contract manufacturing, clinical packaging and cold chain and distribution services, has entered into a non-exclusive collaboration agreement with Advantar Laboratories Inc., a provider of analytical testing, biophysical characterization, drug product formulation and litigation support services to pharma and biopharma companies. The two companies will partner to provide a portfolio of integrated service offerings aimed at avoiding development delays and meeting critical timelines.
The alliance offers customers access to early formulation and analytical method development, aseptic and non-aseptic manufacturing of liquids, powders, gels, and lyophilized drug products, as well as labelling, kitting, storage and shipment services.
Al Hansen, chairman and chief executive officer of Bioserv, said, “This opportunity to ally with Advantar is unique and mutually beneficial as our capabilities align well with theirs. Our collaboration creates multiple synergies that will benefit customers in terms of quality, timeliness and cost-effectiveness.”
Richard Kenley, Ph.D., president and chief executive officer of Advantar, said, “Advantar has teamed successfully with Bioserv in the past, and we are excited about establishing a more formal basis for our alliance. We expect to jointly provide customers with unrivalled offerings in drug product development and manufacturing, and to reliably advance customers’ programs from early development through the approval and launch phases.”

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research